Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Insulet Corporation

Market Cap 1.02TCr 881.6Cr 811.81Cr 762.21Cr 1.43TCr 97TCr 1.45TCr 9.59TCr 3.74TCr 47TCr 3.84TCr 3.76TCr 1,64100Cr P/E Ratio 2026 *
23.8x
P/E Ratio 2027 * 18.5x
Enterprise Value 1.03TCr 888.54Cr 818.21Cr 768.22Cr 1.44TCr 97TCr 1.46TCr 9.67TCr 3.77TCr 48TCr 3.87TCr 3.79TCr 1,65400Cr EV / Sales 2026 *
3.1x
EV / Sales 2027 * 2.53x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day-0.30%
1 week-7.47%
Current month+1.90%
1 month+0.16%
3 months-34.26%
6 months-48.85%
Current year-48.04%
1 week 145.14
Extreme 145.1431
150.89
1 month 140.63
Extreme 140.63
161.35
Current year 140.63
Extreme 140.63
299.8
1 year 140.63
Extreme 140.63
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 27.62
Extreme 27.6201
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Chairman 61 01/01/2019
Director/Board Member 61 27/07/2015
Director/Board Member 59 10/08/2017
Date Insider Type Main position Quantity % Market Cap.
03/06Buy

Director

2,790 0.0040%
03/06Sell

Director

-418 0.0006%
03/06Buy

Director

3,450 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-7.47%-51.83%-48.09% 1.03TCr
+2.20%-0.69%-32.38%-14.67% 15TCr
+1.17%-0.81%-7.51%-8.78% 10TCr
+0.09%+5.39%+63.52%+55.23% 5.57TCr
+0.01%+0.68%-3.77%+53.79% 5.48TCr
-0.25%-4.53%-15.65%-43.87% 4.01TCr
-0.64%+3.00% - - 3.16TCr
-1.43%-6.43%-11.86%-43.77% 2.86TCr
-0.56%-1.52%+46.94%-8.97% 2.34TCr
+0.09%-3.81%-14.22%-5.59% 2.06TCr
Average +0.03%-0.73%-2.97%-7.19% 5.23TCr
Weighted average by Cap. +0.73%-0.10%-6.39%-2.00%

Financials

2026 *2027 *
Net sales 332.31Cr 286.38Cr 263.71Cr 247.6Cr 464.87Cr 31TCr 469.78Cr 3.12TCr 1.21TCr 15TCr 1.25TCr 1.22TCr 53TCr 393.67Cr 339.27Cr 312.41Cr 293.32Cr 550.72Cr 37TCr 556.53Cr 3.69TCr 1.44TCr 18TCr 1.48TCr 1.45TCr 63TCr
Net income 43Cr 37Cr 34Cr 32Cr 60Cr 4.09TCr 61Cr 405.19Cr 157.85Cr 2TCr 162.16Cr 158.72Cr 6.93TCr 57Cr 49Cr 45Cr 42Cr 79Cr 5.34TCr 80Cr 529.91Cr 206.44Cr 2.62TCr 212.07Cr 207.57Cr 9.07TCr
Net Debt 8.06Cr 6.95Cr 6.4Cr 6.01Cr 11Cr 762.37Cr 11Cr 76Cr 29Cr 373.33Cr 30Cr 30Cr 1.29TCr -29Cr -25Cr -23Cr -22Cr -40Cr -2.73TCr -41Cr -270.77Cr -105.49Cr -1.34TCr -108.36Cr -106.06Cr -4.63TCr
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
16/26/16 147.69 $ -0.30% 9,42,276
15/26/15 148.14 $ -1.04% 10,41,258
12/26/12 149.70 $ +0.34% 9,92,614
11/26/11 149.19 $ -1.01% 15,01,808
10/26/10 150.71 $ -5.58% 14,77,891
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
147.69USD
Average target price
242.43USD
Spread / Average Target
+64.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!